HAMPTON, N.J. , Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics , Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market conditions, $250.0 million of shares of its common stock in an underwritten public offering.